Lupin Limited has successfully completed the acquisition of VISUfarma B.V., a leading European ophthalmology specialty pharmaceutical company. The deal was closed on April 1, 2026, through Lupin’s wholly owned subsidiary Nanomi B.V. This strategic move significantly expands Lupin’s eye care portfolio and commercial presence across Europe.
Glimpse:
The acquisition adds more than 60 branded ophthalmic products to Lupin’s portfolio, covering key therapeutic areas such as dry eye disease, glaucoma, eyelid hygiene, blepharitis, retinal health, and specialty nutraceuticals. VISUfarma brings established sales, marketing, and distribution infrastructure in major European markets, supporting Lupin’s long term growth in the high potential specialty care segment.
Lupin Limited has completed the acquisition of VISUfarma B.V., a Netherlands based specialty pharmaceutical company focused exclusively on ophthalmology. The transaction was executed through Lupin’s wholly owned subsidiary, Nanomi B.V., and marks an important milestone in the company’s strategy to grow its global specialty care business.
VISUfarma’s portfolio includes over 60 branded products targeting major eye health conditions such as dry eye, glaucoma, eyelid hygiene, blepharitis, retinal disorders, and specialty nutraceuticals. The company also possesses a well established commercial infrastructure and distribution network across key European countries. This acquisition will enable Lupin to offer a more comprehensive range of ophthalmic solutions and accelerate its expansion in the European market.
The deal was originally announced in late 2025 and was successfully closed on April 1, 2026. Lupin funded the acquisition using internal cash resources. The company expects the integration to be accretive to both revenue growth and margin profile in the coming years.
This strategic step reinforces Lupin’s focus on building a stronger presence in high value therapeutic areas and delivering innovative eye care solutions to patients across Europe.
“This acquisition marks a significant milestone in Lupin’s strategy to expand its specialty care portfolio and strengthen its presence in the European region.”
By
HB Team
